MedTrace Logo

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

NCT00002535 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-26

No results posted yet for this study

Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining biological therapies with indomethacin and cyclophosphamide may kill more tumor cells.

PURPOSE: Phase II trial to compare the effectiveness of indomethacin and biological therapy with or without cyclophosphamide in treating patients who have advanced melanoma that has not responded to previous therapy.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

lymphokine-activated killer cells

BIOLOGICAL

therapeutic tumor infiltrating lymphocytes

DRUG

cyclophosphamide

DRUG

indomethacin

Sponsors & Collaborators

  • St. Luke's Medical Center

    lead OTHER

Principal Investigators

  • John P. Hanson, MD · St. Luke's Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-07-31
Completion
2004-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002535 on ClinicalTrials.gov